Navigation Links
Long-acting beta-agonists most effective step-up therapy for children with poorly controlled asthma
Date:3/2/2010

For children whose asthma is not well controlled and on low doses of inhaled corticosteroids, a long-acting beta-agonist (LABA) may be the most effective of three possible step-up treatments. National Jewish clinician-scientists Stanley Szefler, Joseph Spahn, Ronina Covar Gary Larsen and Lynn Taussig, and colleagues in the NIH-funded Childhood Asthma Research and Education Network published their findings March 2, 2010, online in the New England Journal of Medicine.

"This study gives physicians confidence in using long-acting beta-agonists if a patient is not responding to steroid treatment alone," said said Dr. Szefler, Professor of Pediatrics and Pharmacology at National Jewish Health. "It also shows that children respond quite differently to different step-up therapies. Doctors need to monitor their patients closely and consider switching to a higher dose of inhaled corticosteroids or a leukotriene receptor antagonist if the long-acting beta agonist does not improve asthma control."

Approximately 7 million children in the United States have asthma. The prevalence has more than doubled in the past several decades. Asthma in the United States accounts for 500,000 hospitalizations, 10.5 million physician-office visits, and 3,500 deaths as well as millions of missed school days.

Almost all the children responded differently to the three step-up therapies. About 45 percent of the children responded best to the long-acting beta agonist salmeterol, 28 percent responded best to the leukotriene receptor antagonist montelukast, and 27 responded best to doubling the dose of the inhaled corticoteroid fluticasone.

The study, called Best Add on Therapy Giving Effective Responses (BADGER), compared the effectiveness of three different step-up treatments in 182 children ages 6 to 18. Participants had mild to moderate persistent asthma that was not controlled on low-dose inhaled corticosteroids.

Researchers also found
'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Medical and Research Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
2. Studies Ignite Hope for Long-Acting Allergy Vaccines
3. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
4. Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R)
5. US Back Pain Market Approaches $23 Billion in 2018 - Anticipated Long-Acting, Abuse-Resistant Opioids Drive Value
6. Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven
7. Researchers Create Long-Acting Local Anesthetic
8. Olanzapine Long-Acting Injection (LAI) Efficacy and Safety Data Presented at American Psychiatric Association Annual Meeting
9. New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia
10. New tool to improve patient understanding of long-acting injectable antipsychotic therapies (LAT) unveiled in April issue of Psychiatry 2009
11. Long-Acting Insulin Works Best for Many Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 (HealthDay --, Treatment for lymphoma may lower ... and non-Hodgkin lymphoma, which are cancers of the body,s ... still in their reproductive years. For men, treatment for ... most men regain their fertility within two years of ... about the possibility of this significant side effect before ...
(Date:7/25/2014)... The American Society of Anesthesiologists (ASA) today announced ... (PSH) Learning Collaborative, a national initiative designed to ... surgery. More than 40 leading health care ... the collaborative, which will convene for the first ... July 25-26, in Schaumburg, Ill. , The PSH ...
(Date:7/25/2014)... The new report “Carbohydrase Market ... and Others), by Type (Amylases, Cellulases, and Others), ... Global Trends & Forecasts to 2019", by MarketsandMarkets, ... global Carbohydrase market with analysis of trends, opportunities, ... and values are forecasted on the basis of ...
(Date:7/25/2014)... Richardson, Texas (PRWEB) July 25, 2014 ... years of operations at their office location by expanding ... first of a kind comprehensive visual electro-physiology clinic. , ... and with years of experience in vision problems, patients ... studies can now take advantage of the implementation of ...
(Date:7/25/2014)... European liquid chromatography reagents report defines and segments the ... revenue. The liquid chromatography reagents market in Europe was ... estimated to grow to around $1581.8 million by 2018, ... 2018. , Browse through the TOC of the European ... the in-depth analysis provided. This also provides a glimpse ...
Breaking Medicine News(10 mins):Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4
... According to a study of patients, doctors and family ... When someone has a terminal illness, they may have ... 'living will'. For example they may not wish to ... realistic chance of recovery. But other people, even though ...
... better than conventional treatment for managing asthma attacks. ... immune cells known eosinophils increase// in the airways. ... how targeting this build up of eosinophils in ... asthma attack. ,The conventional treatment consists ...
... is observed that statins reduce the risk of heart attack ... and so lowers the risk of heart disease. This has ... the benefits for the elderly have not been so clear. ... the benefit of treatment with the statin drug pravastatin in ...
... new study observed that people reporting symptoms of anxiety were ... It was long believed that worry gave you ulcers.// ... pylori was a major risk factor, and the link with ... now report that people with generalized anxiety do seem to ...
... with animals say they have located the genes related ... they say it could one day lead to better ... research into this area was only able to locate ... of how the genes work together during memory formation. ...
... researchers observe that stress hormones may be disregulated in ... a hormonal system that helps the body deal with ... production of the stress hormone cortisol by the adrenal ... pains and overwhelming tiredness. It's cause is not well ...
Cached Medicine News:
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... a corporate update and report second quarter 2014 financial ... Friday, August 1, 2014. That same day, Arena will ... Eastern Time (5:30 a.m. Pacific Time). ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/24/2014)... 2014  Parnell Pharmaceuticals Holdings Ltd announces the ... added to Parnell,s already extensive pipeline through a ... biotechnology company. The compounds now known as PAR ... bone regeneration and dermal regeneration, respectively. Parnell has ... the veterinary market with the potential to also ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
... VIENNA, Va., Nov. 3 CEL-SCI Corporation,(NYSE: ... expanded its exclusive licensing,agreement for Multikine(R) with Orient ... from Taiwan. The new,agreement extends the Multikine collaboration ... New Zealand. The licensing agreement,initially focuses on the ...
... - Data presented at the 2008 iSBTc Annual Meeting ... at 11:00 a.m. ET to discuss,results -, BRANFORD, ... announced today preliminary data from an ongoing Phase II,trial ... treatment of patients with unresectable Stage III or Stage ...
Cached Medicine Technology:CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7
... Portable - Battery Powered (6 size AA ... conversion (g, ct, oz, ozt, GN, dwt, ... Counting and Percent Measure functions, Auto Print. ... Optional AC adapter may be ordered for ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... calibration with external weights only (selectable ...
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Medicine Products: